January 28, 2026
1 min read

Antheia seals 2nd series C funding close, hitting more than $175M in a year

Biosynthesis specialist Antheia has topped off its series C funding with a second close, adding $24 million more to its haul. The financing lift brings Antheia’s total funding over the past year to more than $175 million when combined with other capital and new contracts with the U.S. government, according to the company.

Leave a Reply

Your email address will not be published.

Previous Story

NotCo: How AI can help companies align innovation with new US dietary guidelines

Next Story

Cellares’ series D round draws $257M as cell therapy contractor takes operations global

Previous Story

NotCo: How AI can help companies align innovation with new US dietary guidelines

Next Story

Cellares’ series D round draws $257M as cell therapy contractor takes operations global

Latest from Blog

ROFI Drives New Approach to Crop Nutrition

With input costs continuing to pressure farm budgets, some growers are making difficult decisions to reduce fertilizer application rates. While that strategy may ease upfront expenses, it is also accelerating a broader
Go toTop